WA
ATRA icon

Wasatch Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Wasatch Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-335,969
Closed -$12.4M – 250
2023
Q3 		$12.4M Buy
335,969
+4,610
+1% +$205K 0.08% 135
2023
Q2 		$13.3M Sell
331,359
-2,814
-0.8% -$159K 0.08% 145
2023
Q1 		$24.2M Sell
334,173
-1,468
-0.4% -$142K 0.15% 119
2022
Q4 		$27.5M Buy
335,641
+10,186
+3% +$1.06M 0.19% 106
2022
Q3 		$30.8M Buy
325,455
+120,386
+59% +$13.5M 0.21% 101
2022
Q2 		$39.9M Buy
205,069
+52,125
+34% +$8.51M 0.25% 95
2022
Q1 		$35.5M Buy
152,944
+71,923
+89% +$22.9M 0.17% 113
2021
Q4 		$31.9M Sell
81,021
-35,279
-30% -$14.9M 0.13% 140
2021
Q3 		$52M Buy
116,300
+20,770
+22% +$7.44M 0.21% 107
2021
Q2 		$37.1M Buy
95,530
+14,252
+18% +$5.08M 0.15% 132
2021
Q1 		$29.2M Buy
81,278
+2,232
+3% +$987K 0.13% 136
2020
Q4 		$38.8M Sell
79,046
-30,293
-28% -$14M 0.19% 106
2020
Q3 		$35.4M Buy
109,339
+87,087
+391% +$29.7M 0.23% 105
2020
Q2 		$8.11M Buy
22,252
+16,662
+298% +$4.21M 0.06% 171
2020
Q1 		$1.19M Sell
5,590
-38,454
-87% -$12.2M 0.01% 220
2019
Q4 		$18.1M Buy
44,044
+16,972
+63% +$5.85M 0.15% 116
2019
Q3 		$9.56M Buy
27,072
+2,854
+12% +$1.06M 0.09% 139
2019
Q2 		$12.2M Buy
24,218
+7,146
+42% +$5.04M 0.12% 125
2019
Q1 		$17M Buy
17,072
+3,065
+22% +$2.85M 0.18% 95
2018
Q4 		$12.2M Buy
14,007
+13,436
+2,353% +$12.5M 0.16% 100
2018
Q3 		$590K Sell
571
-50
-8% -$48.9K 0.01% 230
2018
Q2 		$571K Buy
621
+215
+53% +$231K 0.01% 260
2018
Q1 		$395K Buy
+406
New +$370K 0.01% 283

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wasatch Advisors's ATRA Position: Q4 2023 in Review

Wasatch Advisors sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 335,969 shares — an estimated $12.4M sold.

Wasatch Advisors first reported a position in ATRA in Q1 2018 and held it in 23 quarters. The position peaked at $52M in Q3 2021. 90 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • Wasatch Advisors reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Wasatch Advisors sold 335,969 Atara Biotherapeutics shares in Q4 2023, an estimated $12.4M.
  • Wasatch Advisors first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 23 quarters.
  • Wasatch Advisors's Atara Biotherapeutics position peaked at $52M in Q3 2021.
  • 90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Wasatch Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.